文献速递免疫规划传染病防控与疫情报告

单克隆抗体混合物SYN023联合狂犬病疫苗的2期随机盲法对照试验

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.
PubMed 文献 · Vaccine · 2021-09-03

这项随机盲法对照2期试验在健康成人中比较了抗狂犬病单克隆抗体混合物SYN023与人血清来源狂犬病免疫球蛋白(RIG)联合市售疫苗的病毒中和活性(RVNA)与安全性。结果显示SYN023组早期RVNA更高,虽然后期较低但仍维持≥0.5 IU/mL至第112天,安全性可接受。

要点

  • SYN023联合疫苗早期RVNA约为HyperRab组的十倍,第14天后较低但仍≥0.5 IU/mL。
  • 累积RVNA点估计83.22%落在相似性界值内,但90%CI下限66.06%未落入。
  • 两组安全性相似,注射部位疼痛SYN023组6%低于HyperRab组22%。

核心结论

  • SYN023联合市售狂犬病疫苗可提供比现有RIG更早的足够抗体覆盖,安全性可接受。
  • 虽出现一定疫苗应答抑制,但相关期间RVNA水平维持≥0.5 IU/mL。

研究设计与样本

  • 随机、盲法、对照2期试验,健康成人志愿者随机分4组:SYN023+Imovax、SYN023+RabAvert、HyperRab+Imovax、HyperRab+RabAvert。
  • 第0天给予1剂RIG(SYN023 0.3 mg/kg或HyperRab 20 IU/mL)及第1剂疫苗,共5剂疫苗。
  • 164例随机受试者均纳入安全性分析,主要终点分析每组至少34例完成全部治疗且有完整RVNA结果。

主要发现

  • 第14天前SYN023组平均RVNA约为HyperRab组的十倍。
  • 第14天后SYN023组平均RVNA较低,但至第112天(研究结束)仍高于广泛认为足够的≥0.5 IU/mL。
  • 累积RVNA点估计为83.22%(SYN023/HyperRab),90%CI为66.06%至104.83%,仅点估计落在方案定义的相似性界值内。
  • 两组RIG+疫苗方案均安全,不良事件多为轻度,未观察到严重或重度相关事件。
  • 治疗相关不良事件发生率两组相似,但注射部位疼痛HyperRab组22%高于SYN023组6%。

关键数值与推荐

  • SYN023给药剂量为0.3 mg/kg,HyperRab为20 IU/mL。
  • RVNA足够水平广泛认为≥0.5 IU/mL。
  • 累积RVNA相似性界值方案定义,点估计83.22%落入,90%CI下限66.06%未落入。

临床怎么用

  • SYN023联合市售疫苗可考虑作为狂犬病暴露后预防的RIG替代选择,早期抗体覆盖更优。
  • 使用SYN023后仍需监测疫苗应答,尽管RVNA在相关期间维持≥0.5 IU/mL。
  • SYN023注射部位疼痛发生率低于HyperRab,安全性可接受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SYN023-002 is a randomized, blinded, controlled study comparing rabies virus neutralizing activity (RVNA) and safety of SYN023, a monoclonal anti-rabies antibody mixture, to human-serum derived anti-rabies immunoglobulin (RIG) when administered with commercially available vaccines to healthy adult volunteers. METHODS: Participants were randomized among 4 treatment groups (SYN023 + Imovax, SYN023 + RabAvert, HyperRab + Imovax, HyperRab + RabAvert). On Day 0, subjects received 1 dose of RIG (0.3 mg/kg SYN023 or 20 IU/mL HyperRab) and their first of 5 vaccine doses. The primary objective was to compare cumulative RVNA between SYN023 and HyperRab recipients. Secondary objectives were to compare safety and to assess SYN023 pharmacokinetics and immunogenicity. RESULTS: All 164 randomized subjects initiated treatment and were included in safety analyses. At least 34 subjects/treatment group received all treatment and had complete RVNA results, thus were included in the primary endpoint analysis. Mean RVNAs were approximately ten-fold higher in SYN023 recipients compared to HyperRab recipients until Day 14. From Day 14 onwards, mean RVNA was lower in SYN023 recipients, but remained above the RVNA level widely considered adequate (≥0.5 IU/mL) through Day 112 (study end). The point estimate of the cumulative RVNA (83.22% SYN023/HyperRab), but not the lower CI bound (90% CI: 66.06%, 104.83%), fell within the protocol-defined similarity margin. Each RIG + vaccine regimen appeared safe with mostly mild AEs and no serious or severe related events observed. Except injection site pain (22% HyperRab recipients vs. 6% SYN023 recipients), treatment-related AEs incidences were similar between RIGs. Anti-SYN023 antibodies were observed but had no apparent effects on PK or safety. CONCLUSIONS: SYN023 administered with commercially available vaccines provides adequate antibody coverage beginning earlier than other commercially available RIGs with an acceptable safety profile. Some suppression of vaccine response occurred, but RVNA levels ≥ 0.5 IU/mL were maintained throughout the relevant period. REGISTRATION: ClinicalTrials.gov #NCT02956746. FUNDING: Synermore biologics.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. McClain JB, Chuang A, Reid C, et al. Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial. Vaccine. 2021. PMID: 34483020. doi:10.1016/j.vaccine.2021.08.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。